Logo Courtesy of Johnson & Johnson

Johnson & Johnson Announces Submission of European Marketing Authorization Applications for Janssen’s Investigational Ebola Vaccine Regimen

Originally Published by Johnson & Johnson

Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have submitted Marketing Authorization Applications (MAAs) to the European Medicines Agency (EMA) seeking licensure for an investigational Ebola vaccine regimen for the prevention of Ebola Virus Disease (EVD) caused by Zaire ebolavirus species. Two MAAs have been submitted in parallel supporting each vaccine in the two-dose regimen (Ad26.ZEBOV, MVA-BN-Filo). In September 2019, the EMA’s Committee for Medicinal Products for Human Use (CHMP) granted an Accelerated Assessment for these applications.

“It is vital that we ensure global preparedness for Ebola given that the world’s largest Ebola outbreaks have taken place in the last six years alone, with the latest currently underway in the Democratic Republic of the Congo (DRC),” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson. “With an understanding that vaccines have an important role to play in countering this epidemic threat, we look forward to the EMA’s review of our applications for licensure.”

The vaccine regimen includes Ad26.ZEBOV as the first dose, which is based on Janssen’s AdVac® technology, and MVA-BN-Filo as the second dose, which is based on Bavarian Nordic’s MVA-BN® technology and is administered approximately eight weeks later. The MAAs are supported by data from Phase 1, 2 and 3 clinical studies evaluating the safety and immunogenicity of the vaccine regimen in adults and children1-7, preclinical studies, and immunobridging analyses. To date, more than 6,500 volunteers across the U.S., Europe and Africa have participated in over 10 clinical studies of the Janssen vaccine.

“Our goal is to deliver a vaccine that can be used both in response to Ebola outbreaks, and also more proactively as a prophylactic tool to help countries protect their populations,” said Johan Van Hoof, M.D., Global Therapeutic Area Head, Vaccines, and Managing Director, Janssen Vaccines & Prevention B.V., Janssen Pharmaceutica N.V. “We are grateful to our many global partners who have helped us reach this important stage of development.”

Johnson & Johnson has made a significant investment in Janssen’s Ebola vaccine regimen since its decision to accelerate the development program in 2014 in response to the West Africa epidemic. The company is grateful to its global partners who have helped to support and co-fund these efforts, including the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), the Innovative Medicines Initiative (IMI) funded through the EU Horizon 2020 programme, and the National Institutes of Health (NIH) at HHS.

Discussions with the U.S. Food and Drug Administration (FDA) are ongoing to define the required data set for filing of the Janssen Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. Janssen is also working in collaboration with the World Health Organization (WHO) to enable registration of the Ebola vaccine regimen in African countries.

On October 31, 2019, the company announced it will provide up to 500,000 regimens of its investigational vaccine for use in a new clinical trial organized by the DRC government and global health stakeholders in an effort to contain the country’s Ebola outbreak.

About Janssen’s Ebola Vaccine Regimen
The Janssen vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely produce one of the Ebola virus proteins in order to trigger an immune response.

Janssen-sponsored Phase 1 studies of the Ebola vaccine regimen have been reported in peer-reviewed journals including JAMA: The Journal of the American Medical Association1,2 and the Journal of Infectious Diseases3,4, and Phase 1, 2 and 3 data were recently presented at the 2019 European Congress of Clinical Microbiology & Infectious Disease (ECCMID)5–7.

Janssen’s investigational Ebola vaccine regimen originates from a collaborative research program with the NIH and received direct funding and preclinical services from the National Institute of Allergy and Infectious Diseases, part of NIH, under Contract Number HHSN272200800056C. Further funding for the Ebola vaccine regimen has been provided in part with federal funds from the Office of the Assistant Secretary for Preparedness and Response, BARDA under Contract Numbers HHSO100201700013C and HHSO100201500008C.

The IMI provided funding through the IMI Ebola+ Program to support a number of consortia that initiated multiple clinical trials and other vaccine development activities. The consortia funded by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking are EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the EU’s Horizon 2020 Framework Programme for Research and Innovation and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Johnson & Johnson also acknowledges its many partners in the ongoing global clinical program for the vaccine regimen, including Bavarian Nordic A/S, Centre Muraz, College of Medicine and Allied Health Sciences (COMAHS, University of Sierra Leone), Grameen Foundation, Inserm, Inserm Transfert, London School of Hygiene & Tropical Medicine (LSHTM), Uganda Virus Research Institute (UVRI), University of Antwerp, University of Oxford, Vibalogics GmbH, Walter Reed Army Institute of Research (WRAIR) and World Vision Ireland.

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Latest News

Comcast Launches Customer Service Program for the Deaf Community in American Sign Language

Originally Published on Comcast.com Comcast and Connect Direct, a subsidiary of Communication Service for the Deaf (CSD), today launched customer service support via American Sign Language (ASL) for Internet Essentials, Xfinity Internet, and general Xfinity billing questions, called ASL Now. With the combined expertise of both companies, Internet Essentials and…

locker firefighters Mississippi Shelton russell fire department Hattiesburg lynching noose

Former Mississippi Firefighter Lieutenant Attributes Noose in Locker Room to ‘Lawless Wild West,’ Not Racism

A noose found in a white lieutenant’s locker in a Hattiesburg, Miss., fire department has caused a rift between Black and white firefighters and has resulted in the resignation of the station’s lieutenant. According to the Associated Press, Shelton Russell, a 22-year veteran with the fire department, left his position…

indicted, baltimore, correctional officers

Judge Releasing Most of 25 Baltimore Correctional Officers Indicted, Accused of Excessive Force and Corruption

Twenty-five Baltimore correctional officers were indicted Tuesday with allegations of assaulting and threatening detainees in a state-run jail, tampering with evidence and falsifying correctional documents. Baltimore City Circuit Court Judge Jennifer Friedman released most of them Wednesday, pending their trial. Baltimore City State’s Attorney Marilyn Mosby’s office secured these 25…

impeachment, Nancy Pelosi, Donald Trump

Nancy Pelosi Says U.S. House of Representatives Will Proceed With Articles of Impeachment Against President Trump

Democratic House Speaker Nancy Pelosi announced Thursday the U.S. House of Representatives will proceed with articles of impeachment against President Donald Trump.  In an announcement on Capitol Hill, Pelosi said “the president leaves us no choice” in pursuing the impeachment. “In the course of today’s events it becomes necessary for…